Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling [Seeking Alpha]
Candel Therapeutics, Inc. (CADL)
Company Research
Source: Seeking Alpha
CADL's aglatimagene has demonstrated statistically significant improvements in disease-free survival and safety, supporting a strong case for FDA approval and commercial launch in 2027. Recent analyst price targets ($26–$30) and market excitement reflect confidence in CADL's late-stage pipeline, especially given the $2.9bn peak revenue estimate for aglatimagene. CADL's robust cash position funds operations into Q1 2028, but commercial execution and payer adoption remain critical risks to monitor post-approval. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » Maskot/DigitalVision via Getty Images Investment Overview The stock of Needham, Massachusetts-based biotech Candel Therapeutics, Inc. ( CADL ) was on the rise in trading yesterday, gaining ~13% for the day, rising to as value of ~$7.3 per share, market cap valuation of ~$530m. More on my IG service If you are interested in keeping up to date with stocks mak
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate CancerGlobeNewswire
- Candel Therapeutics (CADL) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- Candel Therapeutics (CADL) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
CADL
Earnings
- 3/12/26 - Miss
CADL
Sec Filings
- 4/29/26 - Form ARS
- 4/29/26 - Form DEFA14A
- 4/29/26 - Form DEF
- CADL's page on the SEC website